Eikonizo

Cambridge, United States Founded: 2017 • Age: 9 yrs
Brain-penetrant small molecule therapeutics for neurodegenerative diseases are developed.

About Eikonizo

Eikonizo is a Healthcare company based in Cambridge (United States) founded in 2017 by Janice Kranz, Al Schroeder, and William Shaw. Brain-penetrant small molecule therapeutics for neurodegenerative diseases are developed. Eikonizo has raised $2.37 million across 6 funding rounds from investors including Novo Nordisk and HHS. The company has 7 employees. Its chief executive, as recorded, is Janice Kranz. Eikonizo offers products and services including HDAC6 Inhibitors. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is EIKONIZO THERAPEUTICS, INC. Its competitors include T3D Therapeutics, Longeveron and Alzheon; 3 of its 3 listed competitors have raised funding.

Company details

Eikonizo was founded in 2017 in Cambridge, United States, and focuses on the biotechnology sector. Small molecule therapeutics that penetrate the brain are developed to address neurodegenerative diseases. The lead program targets selective histone deacetylase 6 (HDAC6) inhibitors for conditions such as Alzheimers disease and amyotrophic lateral sclerosis. Operations center on advancing these inhibitors through research and development stages.

  • Headquarters Cambridge, United States
  • Employees 7
  • Founders Janice Kranz, Al Schroeder, William Shaw
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website eikonizo.com
  • Social LinkedIn X
  • Legal Name Eikonizo Therapeutics, Inc.
Operational Areas
Key Metrics
  • Total Equity Funding
    $2.37M (USD)

    in 6 rounds

  • Investors
  • Employee Count
    7

Products & Services of Eikonizo

Eikonizo offers a comprehensive portfolio of products and services, including HDAC6 Inhibitors.

HDAC6 Inhibitors
Therapeutics

Small molecules that inhibit HDAC6 to improve transport and reduce aggregates in diseases

Funding Insights of Eikonizo

Eikonizo has successfully raised a total of $2.37M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $2.37M
  • Total Rounds 6
  • First Round $2M

    (Mar 2018)

  • Investors Count 2

All 6 funding rounds of Eikonizo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2024Seed––
Sep 2020$509,669Grant––
Sep 2020$299,983Grant––
May 2018Debt – Conventional––
–
May 2018$371,352Seed––
–
Mar 2018$2MSeed––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Eikonizo

Eikonizo has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Novo Nordisk and HHS.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
1923novonordisk.comBagsvaerd, Denmark
Public health and human services are overseen by HHS.
1953hhs.gov
Premium access

Investor details for Eikonizo

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Eikonizo

15 people are tracked at Eikonizo (7 in leadership, 6 in board & advisors, 2 in team); the tracked headcount is 7.

NameRoleGroup
Janice Kranz
Co-Founder & CEOLeadership
Al Schroeder
Co-Founder & DirectorLeadership
William Shaw
Co-Founder & DirectorLeadership
Alix Gregory
Head of OperationsLeadership
Tonya Gilbert
Director, Translational ResearchLeadership
Frederick 'Al' Schroeder
Co-Founder and Director of R&DLeadership
Florence Wagner
Director, Medicinal ChemistryLeadership
Kevin Kinsella
DirectorBoard & advisors
Stuart L. Schreiber
AdvisorBoard & advisors
Brad Rosenblum
AdvisorBoard & advisors
Stacie Weninger
DirectorBoard & advisors
Leonard Petrucelli
AdvisorBoard & advisors
Todd Cohen
AdvisorBoard & advisors
Lauren Evans
Senior ScientistTeam
Rebecca James (she/her), Ph.D.
Research Scientist IITeam
Premium access

Complete people profiles for Eikonizo

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Eikonizo

3 dated milestones of Eikonizo across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Eikonizo is founded.
  2. Funding First funding round of $2.0M.
  3. Funding Latest funding round, Seed,.

Competitors of Eikonizo

Eikonizo has 3 listed competitors in our database, 3 of them funded. They include T3D Therapeutics, Longeveron and Alzheon.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
t3dtherapeutics.com2013Durham, United States$33.02M
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
longeveron.com2014Miami, United States$1.05M23
Cellular therapies for aging-related and life-threatening conditions are developed.
alzheon.com2013Framingham, United States$195.25M
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
Premium access

Detailed competitors of Eikonizo

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Neurology

3 companies that operate in the same segment as Eikonizo (Neurology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Developer of therapeutics for psychiatric and neurologic diseases
2002New York, New York, United StatesUSD 80.87 MUSD 250.31 M600
Biologics platform developed for intracellular delivery in rare diseases.
2016Boston, Massachusetts, United StatesUSD 175.25 MUSD 25.42 M183
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Eikonizo

Premium access

Complete news archive for Eikonizo

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Eikonizo

Eikonizo was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Eikonizo is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Janice Kranz is the CEO of Eikonizo, as recorded in our data. They have also founded this company.

Eikonizo is a funded company, having raised a total of $2.37M across 6 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Mar 2018.

Eikonizo has 7 employees.

Eikonizo was founded in 2017 in Cambridge, United States, and focuses on the biotechnology sector. Small molecule therapeutics that penetrate the brain are developed to address neurodegenerative diseases. The lead program targets selective histone deacetylase 6 (HDAC6) inhibitors for conditions such as Alzheimers disease and amyotrophic lateral sclerosis. Operations center on advancing these inhibitors through research and development stages.

Eikonizo's top competitors include Alzheon, Longeveron and T3D Therapeutics.

Eikonizo offers HDAC6 Inhibitors.

Eikonizo has 2 investors. Key investors include Novo Nordisk, and HHS.

Eikonizo operates through Eikonizo Therapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available